Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00048737 | Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies | PHASE1 | COMPLETED | 70 | — | — | Oct 1, 2002 | Dec 1, 2011 | Jun 13, 2013 | 1 | United States |
Graft failure is defined as either lack of hematologic recovery or lack of or loss of detectable donor cells.
| Arm | Type | Description |
|---|---|---|
| 90Y Zevalin in ASCT | EXPERIMENTAL | Allogeneic Stem Cell (AST) Transplantation with 90Y Zevalin/Cyclophosphamide/Fludarabine as a preparative regimen. |
| Name | Type | Description |
|---|---|---|
| Zevalin Radioimmunotherapy | DRUG | Escalating single dose of 90Y Zevalin 0.2-0.3-0.4 mCi/kg |
| Rituximab | DRUG | 250 mg/m\^2 on day 1 and day 8 |
| Fludarabine | DRUG | 30 mg/m\^2/day for 3 days |
| Cyclophosphamide | DRUG | 750 mg/m\^2/day for 3 days, given on the same days as fludarabine, at 4-hour intervals |
| Allogeneic Stem Cell Transplantation | PROCEDURE | Allogeneic stem cell transplantation 2 days after chemotherapy |
Inclusion Criteria: 1. Patients in relapse or considered at high risk for relapse or refractory CD-20-positive B-cell NHL or CLL. Patients considered for high risk of relapse are patients who do not achieve complete response (CR) with frontline chemotherapy, CLL is Richter's and CLL with high risk ...